Prime Medicine, Inc. Common Stock earnings per share and revenue
On 07. Nov. 2025, PRME reported earnings of -0.32 USD per share (EPS) for Q3 25, missing the estimate of -0.25 USD, resulting in a -23.98% surprise. Revenue reached 1.23 million, compared to an expected 1.05 million, with a 17.04% difference. The market reacted with a -8.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 2.35 million USD, implying an decrease of -21.88% EPS, and increase of 92.11% in Revenue from the last quarter.
FAQ
What were Prime Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Prime Medicine, Inc. Common Stock reported EPS of -$0.32, missing estimates by -23.98%, and revenue of $1.23M, 17.04% above expectations.
How did the market react to Prime Medicine, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -8.85%, changed from $4.18 before the earnings release to $3.81 the day after.
When is Prime Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for 26. Feb. 2026.
What are the forecasts for Prime Medicine, Inc. Common Stock's next earnings report?
Based on 14
analysts, Prime Medicine, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $2.35M for Q4 2025.